证券代码：601607 证券简称：上海医药 公告编号：临 2025-052 上海医药集团股份有限公司 关于参加上海国有控股上市公司2024年度 集体业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、说明会类型 本次业绩说明会以"上证路演中心视频直播和网络互动"形式召开，公司将 针对 2024 年度经营情况及未来发展战略等情况与投资者进行互动交流和沟通，在 信息披露允许的范围内解答投资者普遍关注的问题。 二、说明会召开的时间、地点 （一）会议主题：上海国有控股上市公司 2024 年度集体业绩说明会 （二）会议召开时间：2025 年 5 月 9 日下午 13:30-16:45 重要内容提示： （网址：https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心视频直播和网络互动 上海医药集团股份有限公司（以下简称："公司"）已于 2025 年 3 月 28 日 披露公司 2024 年年度报告，为进一步加强公司与投资者的沟通交流，让广大投资 者能深入了解公司经营情况、未来发展战略 ...

Core Insights - Shanghai Pharmaceuticals reported a revenue of 70.763 billion yuan for Q1 2025, representing a year-on-year growth of 0.87% [1] - The company achieved a net profit attributable to shareholders of 1.333 billion yuan during the same period [1] Revenue Breakdown - The pharmaceutical manufacturing segment generated sales of 5.885 billion yuan [1] - The pharmaceutical commercial segment accounted for sales of 64.878 billion yuan [1] Business Growth Areas - The import agency business achieved sales of 8.6 billion yuan, reflecting a year-on-year increase of 9.0% [1] - The innovative drug business reported sales of 12.5 billion yuan, with a significant growth of 23.2% [1] - The CSO (Contract Sales Organization) business saw a revenue increase of 9.89% [2] - The health equipment segment generated sales of 10.9 billion yuan, marking a growth of 6.9% [2] Strategic Initiatives - Shanghai Pharmaceuticals launched the "Lingang New Area Medical Device Import and Export Service Center" to facilitate the import of urgently needed drugs and rare disease medications [1] - The company established strategic partnerships with firms like Ansell and Kangfang Biotech to enhance the commercialization of new drugs [1]

重要公告： 福田汽车：拟不超25亿元参与认购北汽蓝谷定增股份 中国石化：一季度净利润132.64亿元同比下降27.6% 沪市重要公告： 药明康德：一季度净利润36.72亿元同比增长89.06% 中金公司：一季度净利润20.42亿元同比增长64.85% 赛特新材：董事长自愿放弃领薪高管人员自愿降薪 上海医药：一季度净利润13.33亿元同比下降13.56% 上海医药（601607）4月28日晚间发布一季报，2025年一季度实现营业收入707.63亿元，同比增长 0.87%；净利润13.33亿元，同比下降13.56%。其中，工业板块贡献利润5.32亿元；商业板块贡献利润 8.34亿元；主要参股企业贡献利润1.96亿元。 传音控股：一季度净利润4.9亿元同比下降69.87% 传音控股（688036）4月28日晚间发布一季报，2025年第一季度营收为130.04亿元，同比下降25.45% （调整后）；净利润为4.9亿元，同比下降69.87%（调整后）。净利润下降主要是受市场竞争以及供应 链成本综合影响，营业收入及毛利额减少所致。 浙能电力：一季度净利润10.74亿元同比下降40.81% 浙能电力（600023）4月28 ...

Investment Rating - The report does not explicitly state an investment rating for the cinnamon health food industry Core Insights - The cinnamon health food industry is driven by health demand, with a broad market outlook due to the rich raw material resources and increasing consumer recognition and acceptance [4][11][14] - The industry has experienced stable historical growth, primarily influenced by limited supply increases and the need for greater consumer awareness, with price increases being the main growth driver [4][33] - Future growth is expected to be supported by policy backing and an aging population, which will enhance supply and consumer demand, leading to market expansion [4][35] Industry Definition - Cinnamon health foods are defined as health products primarily made from cinnamon, which is widely used in traditional medicine and has multiple health benefits [5] Industry Classification - The cinnamon health food industry can be classified into various forms, including liquor, capsules, tablets, granules, oral liquids, pills, pastes, and powders [6][10] Industry Characteristics - Rich raw material resources: China leads the world in cinnamon planting area and production, ensuring a stable supply for the industry [11][12] - Clear regulatory boundaries: The industry is subject to specific safety and functionality standards, providing a balanced regulatory environment that encourages innovation [13] - Sustained consumer demand: The dual role of cinnamon as both a traditional medicine and a spice enhances consumer acceptance and demand for cinnamon health foods [14] Development History - The industry has evolved from initial exploration to maturity, with significant growth driven by policy support and market demand [15][16] - The establishment of a dual-channel registration and filing mechanism for health foods has accelerated product innovation and market responsiveness [18] Industry Chain Analysis - The industry chain includes sustainable raw material sourcing, technological innovation in production, and strong downstream market demand for health products [19][20] - Upstream supply is critical, with the planting area and quality of cinnamon directly impacting the industry [20] - Midstream processing requires advanced technology to ensure product quality and market competitiveness [21] Market Size - The market size of the cinnamon health food industry grew from 1.402 billion RMB in 2020 to 1.578 billion RMB in 2024, with a compound annual growth rate of 3.00% [32] - Future projections estimate the market will reach 1.902 billion RMB by 2029, with a compound annual growth rate of 3.99% [32] Price Trends - The average price of cinnamon health foods is expected to rise from 205.01 RMB to 215.03 RMB between 2025 and 2029, driven by increased consumer demand for quality health products [36] Competitive Landscape - The industry is characterized by significant product homogeneity, with leading companies like Weisiya Health and others competing in a relatively small market [41][42] - Smaller companies may find opportunities for growth through differentiated strategies, as the market does not heavily rely on large listed companies [45]

Investment Rating - The report does not explicitly state an investment rating for the cinnamon health food industry Core Insights - The cinnamon health food industry is driven by health demand, with a broad market outlook due to the rich raw material resources and increasing consumer recognition and acceptance [4][11] - The industry has experienced stable historical growth, primarily influenced by limited supply increases and the need for greater consumer awareness, with price increases being the main growth driver [4][34] - Future growth is expected to be supported by policy backing and an aging population, which will enhance supply and elevate consumer demand, leading to market expansion [4][35] Industry Definition - Cinnamon health foods are defined as health products primarily made from cinnamon, which is widely recognized for its multiple health benefits [5] Industry Classification - The cinnamon health food industry can be categorized into various forms, including tinctures, capsules, and tablets [6] Industry Characteristics - Rich raw material resources: China leads the world in cinnamon planting area and production, ensuring a stable supply for the industry [11][12] - Clear regulatory boundaries: The industry is subject to specific safety and functionality standards, providing a balanced regulatory environment that encourages innovation [13] - Sustained consumer demand: The dual role of cinnamon as both a traditional medicine and a widely used spice enhances consumer acceptance of cinnamon health foods [14] Development History - The industry has evolved from initial exploration to a mature stage, with significant growth driven by policy support and market demand [15][16] Industry Chain Analysis - The industry chain includes sustainable raw material sourcing, technological innovation in production, and strong downstream market demand for health products [19][20] Market Size - The market size of the cinnamon health food industry grew from 1.402 billion RMB in 2020 to 1.578 billion RMB in 2024, with a compound annual growth rate of 3.00% [32] - Future projections estimate the market will expand from 1.626 billion RMB in 2025 to 1.902 billion RMB in 2029, with a compound annual growth rate of 3.99% [32] Price Trends - The average price of cinnamon health foods is expected to rise from 205.01 RMB to 215.03 RMB between 2025 and 2029, driven by increasing consumer demand for quality health products [36] Competitive Landscape - The industry is characterized by significant product homogeneity, with leading companies like Weisiya Health and others competing in a relatively fragmented market [41][42] - Smaller companies may find opportunities for growth through differentiated strategies, as the market does not heavily rely on large listed companies [45]

Group 1: Smartphone Market - Xiaomi has regained the top position in the Chinese smartphone market after ten years, with a shipment of 13.3 million units and a market share of 18.6%, representing a year-on-year growth of 39.9% [2] - Huawei shipped 11.2 million units with a market share of 15.7%, showing a year-on-year increase of 10% [2] - Apple experienced a decline, shipping 9.8 million units and a market share of 13.7%, down 10% year-on-year [2] Group 2: Corporate Developments - Apple is restructuring its teams, moving its robotics team to the hardware department, indicating dissatisfaction with its AI and machine learning leadership [3] - Cyberspace Group has submitted an application for listing on the Hong Kong Stock Exchange, with joint sponsors being CICC and China Galaxy International [4] - Warner Pharmaceuticals has received approval for its bismuth potassium citrate granules, which will enhance its market competitiveness [12] Group 3: Financial Performance - CICC reported a net profit of 2.042 billion yuan for Q1, a year-on-year increase of 64.85%, with revenues of 5.721 billion yuan, up 47.69% [9] - WuXi AppTec achieved a net profit of 3.672 billion yuan in Q1, marking a year-on-year growth of over 89% [10] - Shanghai Pharmaceuticals reported a net profit of 1.333 billion yuan in Q1, down 13.56% year-on-year [11] Group 4: Consumer Goods - Lao Feng Xiang reported a net profit of 613 million yuan in Q1, a decrease of 23.55% year-on-year, with revenues of 17.521 billion yuan, down 31.64% [13] - Three squirrels reported a net profit of 239 million yuan in Q1, a decline of 22.46% year-on-year, with revenues of 3.723 billion yuan, up 2.13% [16] Group 5: New Initiatives - China Petroleum & Chemical Corporation has commenced construction on a 30,000-ton carbon fiber project, expected to be completed by 2027, supporting the new materials industry [22][23] - ZTE is entering the companion robot market, planning to launch products focused on security monitoring and emotional companionship [6] Group 6: Market Trends - TikTok is implementing new regulations to combat malicious marketing accounts, introducing a health score mechanism for accounts [8] - The dining reservation volume for the upcoming holiday has surged, with Haidilao receiving over 25,000 reservations for the first day of the holiday [15]

Core Viewpoint - The China Securities Index for the medical industry has shown a decline in performance over various time frames, indicating potential challenges within the sector [2]. Group 1: Index Performance - The China Securities Index for the medical industry has decreased by 5.99% over the past month, 1.12% over the past three months, and 6.26% year-to-date [2]. - The index was established with a base date of December 31, 2021, set at 1000.0 points [2]. Group 2: Index Composition - The top ten weighted companies in the index include: - Mindray Medical (14.15%) - Aier Eye Hospital (9.35%) - United Imaging (8.03%) - Aimeike (4.1%) - Huatai Medical (3.87%) - New Industry (3.16%) - Shanghai Pharmaceuticals (3.11%) - Yuyue Medical (3.06%) - Yifeng Pharmacy (2.49%) - Meinian Onehealth (2.45%) [2]. - The index's holdings are primarily listed on the Shenzhen Stock Exchange (56.76%) and the Shanghai Stock Exchange (43.24%) [2]. Group 3: Sector Allocation - The sector allocation within the index is as follows: - Medical Devices: 34.77% - Medical Consumables: 22.92% - Pharmaceutical Commerce: 15.73% - Medical Services: 14.44% - In Vitro Diagnostics: 12.14% [2]. Group 4: Sample Adjustment - The index samples are adjusted biannually, with adjustments occurring on the next trading day following the second Friday of June and December [3]. - Weight factors are generally fixed until the next scheduled adjustment, with temporary adjustments made in response to significant events affecting sample companies [3].

香港交易及結算所有限公司和香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 上 海 醫 藥 集 團 股 份 有 限 公 司 Shanghai Pharmaceuticals Holding Co., Ltd. * （於中華人民共和國註冊成立的股份有限公司） （股份代碼：02607） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條而作出。 茲載列上海醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(http://www.sse.com.cn) 刊登的《上海醫藥集團股份有限公司第八屆董事會第二十二次會議決議公告》僅供參閱。 承董事會命 上海醫藥集團股份有限公司 楊秋華 董事長 中國上海，2025 年 4 月 29 日 於本公告日期，本公司的執行董事為楊秋華先生、沈波先生、李永忠先生及董明 先生；非執行董事為張文學先生；以及獨立非執行董事為顧朝陽先生、霍文遜先 生、王忠先生及萬鈞女士。 * 僅供識別 2、《关于召开公司 2024 年年度股东大会 ...

Financial Performance - The company achieved operating revenue of RMB 70.763 billion in Q1 2025, representing a year-on-year growth of 0.87%[10] - The net profit attributable to shareholders was RMB 1.333 billion, a decrease of 13.56% year-on-year, with the industrial segment contributing RMB 532 million and the commercial segment contributing RMB 834 million[10] - Total operating revenue for the reporting period was approximately 70.76 billion RMB, an increase of 0.87% compared to the previous year[20] - Net profit attributable to shareholders decreased by 13.56% to approximately 1.33 billion RMB[20] - Net profit for Q1 2025 was ¥1.64 billion, a decrease of 12.06% from ¥1.87 billion in Q1 2024[36] - Earnings per share for Q1 2025 were ¥0.36, down from ¥0.42 in Q1 2024[38] Research and Development - Research and development expenses amounted to RMB 612 million, with R&D costs at RMB 497 million remaining stable year-on-year[11] - Multiple innovative drug research pipelines are progressing, including I001 for hypertension, which has submitted supplementary materials for review[12] - The company has established several key laboratories and centers to enhance its R&D capabilities in the biopharmaceutical industry[13] - The company is actively collaborating with academic institutions to advance research in traditional Chinese medicine and improve product quality[17] - The company reported a decrease in R&D expenses to ¥497 million in Q1 2025 from ¥501 million in Q1 2024[35] - Research and development expenses for Q1 2025 were 101,363,079.95, down from 123,475,536.87 in Q1 2024, indicating an 18% reduction[50] Product Development and Approvals - The company received production approvals for two products and submitted eight additional products for production during the reporting period[13] - A total of 77 products (106 specifications) have passed quality and efficacy consistency evaluations as of the end of the reporting period[13] - The company is implementing a strategy to ensure the quality of medicinal materials through a comprehensive national resource network and standardized management models[15] Business Segments Performance - Innovative business segments, including import agency and innovative drug services, have shown good growth during the reporting period[16] - The company's total import agency business achieved sales revenue of 8.6 billion RMB, a year-on-year increase of 9.0%[18] - The innovative drug full life cycle service generated sales revenue of 12.5 billion RMB, with a year-on-year growth of 23.2%[18] - The CSO business saw a revenue increase of 9.89% year-on-year[18] - The medical device health business reported sales revenue of 10.9 billion RMB, reflecting a year-on-year growth of 6.9%[18] Cash Flow and Liquidity - The net cash flow from operating activities improved by 59.73%, reaching approximately -2.20 billion RMB[20] - In Q1 2025, the cash inflow from operating activities was CNY 72.34 billion, an increase of 3.9% from CNY 67.81 billion in Q1 2024[40] - The net cash flow from operating activities was -CNY 2.20 billion, an improvement from -CNY 5.47 billion in the same period last year[41] - Cash inflow from investment activities totaled CNY 16.46 billion, up from CNY 10.53 billion in Q1 2024, marking a 56% increase[41] - Cash inflow from financing activities reached CNY 23.25 billion, compared to CNY 21.52 billion in Q1 2024, reflecting an 8% increase[42] - The company experienced a net decrease in cash and cash equivalents of approximately ¥1.63 billion in Q1 2025, compared to a decrease of approximately ¥1.08 billion in Q1 2024[54] Assets and Liabilities - Total assets at the end of the reporting period were approximately 225.87 billion RMB, a 2.11% increase from the previous year[20] - Total liabilities increased to CNY 130,813,134,867.82 from CNY 126,038,386,279.10, marking an increase of approximately 3.1%[31] - Short-term borrowings rose significantly to CNY 42,909,928,847.57 from CNY 38,064,098,967.71, reflecting an increase of about 12.4%[31] - Total liabilities as of March 31, 2025, amounted to ¥140.57 billion, an increase from ¥137.47 billion as of December 31, 2024[32] - Total non-current liabilities were ¥9.76 billion as of March 31, 2025, down from ¥11.43 billion as of December 31, 2024[32] Shareholder Information - The total number of shares outstanding as of March 31, 2025, is 3,708,361,809, with A-shares accounting for 2,789,289,105 and H-shares for 919,072,704[28] - The number of ordinary shareholders reached 80,068, with A-share holders accounting for 78,411 and H-share holders for 1,657[28] - Shareholders' equity attributable to the parent company increased to ¥73.01 billion as of March 31, 2025, from ¥71.68 billion as of December 31, 2024[32] Future Outlook - The company is set to implement new accounting standards starting in 2025, which may impact future financial reporting[54]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 证券代码：601607 证券简称：上海医药 公告编号：临2025-051 上海医药集团股份有限公司（以下简称"本公司"或"上海医药"）第八届 董事会第二十二次会议（以下简称"本次会议"）于 2025 年 4 月 28 日在上海市 太仓路 200 号上海医药大厦 1101 会议室以现场方式召开。本次会议应到董事九 名，实到董事九名，符合《中华人民共和国公司法》和本公司章程关于董事会召 开法定人数的规定。本次会议由杨秋华董事长主持，监事和部分高级管理人员列 席本次会议。董事会会议审议情况具体如下： 1、《2025 年第一季度报告》 上海医药集团股份有限公司 第八届董事会第二十二次会议决议公告 特此公告。 上海医药集团股份有限公司 董事会 二零二五年四月二十九日 表决结果：赞成 9 票，反对 0 票，弃权 0 票 本议案前期已提交公司第八届董事会审计委员会第十二次会议审议通过，同 意提交董事会审议。 2、《关于召开公司 2024 年年度股东大会的议案》 同意召开公司 2024 年 ...